Incidence and Risk Factors for Leptomeningeal Carcinomatosis in Breast Cancer Patients with Parenchymal Brain Metastases.
- Author:
Jong Myung JUNG
1
;
Sohee KIM
;
Jungnam JOO
;
Kyung Hwan SHIN
;
Ho Shin GWAK
;
Seung Hoon LEE
Author Information
1. Department of Neurosurgery, Seoul National University College of Medicine, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Brain metastasis;
Breast cancer;
Leptomeningeal carcinomatosis;
Surgery;
Whole brain radiation therapy
- MeSH:
Brain;
Breast;
Breast Neoplasms;
Chemotherapy, Adjuvant;
Humans;
Incidence;
Magnetic Resonance Spectroscopy;
Meningeal Carcinomatosis;
Neoplasm Metastasis;
Retrospective Studies;
Risk Factors;
Streptothricins
- From:Journal of Korean Neurosurgical Society
2012;52(3):193-199
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: The objective of study is to evaluate the incidence of leptomeningeal carcinomatosis (LMC) in breast cancer patients with parenchymal brain metastases (PBM) and clinical risk factors for the development of LMC. METHODS: We retrospectively analyzed 27 patients who had undergone surgical resection (SR) and 156 patients with whole brain radiation therapy (WBRT) as an initial treatment for their PBM from breast cancer in our institution and compared the difference of incidence of LMC according to clinical factors. The diagnosis of LMC was made by cerebrospinal fluid cytology and/or magnetic resonance imaging. RESULTS: A total of 27 patients (14%) in the study population developed LMC at a median of 6.0 months (range, 1.0-50). Ten of 27 patients (37%) developed LMC after SR, whereas 17 of 156 (11%) patients who received WBRT were diagnosed with LMC after the index procedure. The incidence of LMC was significantly higher in the SR group compared with the WBRT group and the hazard ratio was 2.95 (95% confidence interval; 1.33-6.54, p<0.01). Three additional factors were identified in the multivariable analysis : the younger age group (<40 years old), the progressing systemic disease showed significantly increased incidence of LMC, whereas the adjuvant chemotherapy reduce the incidence. CONCLUSION: There is an increased risk of LMC after SR for PBM from breast cancer compared with WBRT. The young age (<40) and systemic burden of cancer in terms of progressing systemic disease without adjuvant chemotherapy could be additional risk factors for the development of LMC.
